CN105105892A - 一种药物洗脱球囊 - Google Patents
一种药物洗脱球囊 Download PDFInfo
- Publication number
- CN105105892A CN105105892A CN201510471362.3A CN201510471362A CN105105892A CN 105105892 A CN105105892 A CN 105105892A CN 201510471362 A CN201510471362 A CN 201510471362A CN 105105892 A CN105105892 A CN 105105892A
- Authority
- CN
- China
- Prior art keywords
- medicine
- paclitaxel
- sacculus
- hirudin
- medication coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 196
- 238000010828 elution Methods 0.000 title claims abstract description 47
- 229940079593 drug Drugs 0.000 title claims description 80
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 85
- 102000007625 Hirudins Human genes 0.000 claims abstract description 82
- 108010007267 Hirudins Proteins 0.000 claims abstract description 82
- 229940006607 hirudin Drugs 0.000 claims abstract description 82
- 229930012538 Paclitaxel Natural products 0.000 claims description 98
- 229960001592 paclitaxel Drugs 0.000 claims description 98
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 98
- 239000000203 mixture Substances 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000005507 spraying Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000005516 engineering process Methods 0.000 claims description 9
- 238000000889 atomisation Methods 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 abstract description 14
- 238000000576 coating method Methods 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 10
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 6
- 208000007536 Thrombosis Diseases 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002966 stenotic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
- 230000001629 suppression Effects 0.000 description 13
- 229940000425 combination drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 208000037803 restenosis Diseases 0.000 description 9
- 235000013877 carbamide Nutrition 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 6
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000013146 percutaneous coronary intervention Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 108010019160 Pancreatin Proteins 0.000 description 4
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 241000237903 Hirudo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 238000010422 painting Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101710194906 Hirudin-3 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108010001953 Protein C Inhibitor Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PVBALTLWZVEAIO-UHFFFAOYSA-N diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 description 1
- 229960001845 diodone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- -1 prednisone etc. Chemical compound 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471362.3A CN105105892B (zh) | 2015-08-04 | 2015-08-04 | 一种药物洗脱球囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471362.3A CN105105892B (zh) | 2015-08-04 | 2015-08-04 | 一种药物洗脱球囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105105892A true CN105105892A (zh) | 2015-12-02 |
CN105105892B CN105105892B (zh) | 2017-03-29 |
Family
ID=54654191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510471362.3A Active CN105105892B (zh) | 2015-08-04 | 2015-08-04 | 一种药物洗脱球囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105105892B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943209A (zh) * | 2016-06-08 | 2016-09-21 | 葛晨亮 | 新型药物涂层球囊 |
CN115569240A (zh) * | 2022-09-15 | 2023-01-06 | 辽宁垠艺生物科技股份有限公司 | 一种药物涂层塑料囊及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1674853A (zh) * | 2002-08-26 | 2005-09-28 | 徐力健 | 用于医疗移植物的药物洗脱涂层 |
CN101264347A (zh) * | 2007-11-27 | 2008-09-17 | 天津百畅医疗器械科技有限公司 | 缓解血管再狭窄而涂敷在球囊导管气囊表面的药物涂层 |
CN101361686A (zh) * | 2008-10-13 | 2009-02-11 | 王显 | 一种血管药物支架 |
US20100189876A1 (en) * | 2001-01-05 | 2010-07-29 | Abbott Cardiovascular Systems Inc. | Balloon Catheter for Delivering Therapeutic Agents |
US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
CN103316382A (zh) * | 2013-05-10 | 2013-09-25 | 张金萍 | 携带保护套管的紫杉醇药物球囊及其制备方法 |
CN104511084A (zh) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | 一种球囊导管 |
-
2015
- 2015-08-04 CN CN201510471362.3A patent/CN105105892B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100189876A1 (en) * | 2001-01-05 | 2010-07-29 | Abbott Cardiovascular Systems Inc. | Balloon Catheter for Delivering Therapeutic Agents |
CN1674853A (zh) * | 2002-08-26 | 2005-09-28 | 徐力健 | 用于医疗移植物的药物洗脱涂层 |
US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
CN101264347A (zh) * | 2007-11-27 | 2008-09-17 | 天津百畅医疗器械科技有限公司 | 缓解血管再狭窄而涂敷在球囊导管气囊表面的药物涂层 |
CN101361686A (zh) * | 2008-10-13 | 2009-02-11 | 王显 | 一种血管药物支架 |
CN103316382A (zh) * | 2013-05-10 | 2013-09-25 | 张金萍 | 携带保护套管的紫杉醇药物球囊及其制备方法 |
CN104511084A (zh) * | 2014-12-30 | 2015-04-15 | 深圳市信立泰生物医疗工程有限公司 | 一种球囊导管 |
Non-Patent Citations (4)
Title |
---|
张和韡等: "水蛭素的研究进展", 《中国中西医结合肾病杂志》 * |
王显等: "紫杉醇水蛭素复合物对兔血管平滑肌细胞和内皮细胞增殖与迁移的影响", 《中国循证心血管医学杂志》 * |
王显等: "紫杉醇水蛭素复合物微孔载药支架对兔腹主动脉内膜的影响", 《中国循证心血管医学杂志》 * |
王航等: "水蛭素的分子改造与结构修饰研究进展", 《西北药学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105943209A (zh) * | 2016-06-08 | 2016-09-21 | 葛晨亮 | 新型药物涂层球囊 |
CN115569240A (zh) * | 2022-09-15 | 2023-01-06 | 辽宁垠艺生物科技股份有限公司 | 一种药物涂层塑料囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105105892B (zh) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104014001B (zh) | 改良的涂覆药物的医药产品及其制造和应用 | |
CN104623740B (zh) | 一种药物球囊及其制备方法 | |
JP6756664B2 (ja) | 薬剤を分散させるための医療器具 | |
CN101417152B (zh) | 与过氧化物酶体增生物激活受体刺激剂联合的mTOR抑制剂的局部血管递送 | |
CN103748147B (zh) | 等离子体改性的医疗设备和方法 | |
CN107635593A (zh) | 用于非血管狭窄的药物涂布的球囊导管 | |
JP2019080968A (ja) | バルーンカテーテルに対する長時間作用型リムス製剤 | |
MXPA04003906A (es) | Endoprotesis vacular o injerto revestido o impregnado con inhibidores de quinasa de tirosina de proteina y metodo para utilizar los mismos. | |
CN101474455B (zh) | 一种储存和释放多种药物的纳米级微孔结构药物洗脱器械及制备方法 | |
CN101365447A (zh) | 用于治疗再狭窄病变的含有纳米粒子的药物组合物 | |
Wei et al. | REDV/Rapamycin-loaded polymer combinations as a coordinated strategy to enhance endothelial cells selectivity for a stent system | |
CN106806948A (zh) | PI3K/mTOR双重抑制剂的用途 | |
CN105105892A (zh) | 一种药物洗脱球囊 | |
CN101455863A (zh) | 药物洗脱冠脉支架 | |
CN107496998B (zh) | 外周药物洗脱支架及其制备和应用 | |
CN101584888A (zh) | 一种药物释放血管支架及其制备方法 | |
CN101239216A (zh) | 一种新型球囊扩张导管 | |
CN101496813B (zh) | 组合物在制备抗组织增生(血管再狭窄)支架的药物涂层中的应用 | |
CN106237330A (zh) | 用于动脉血管病变扩张载药球囊的复配药物及载药球囊 | |
CN104707185A (zh) | 一种银杏内酯b复合药物洗脱支架 | |
Roy-Chaudhury et al. | Novel therapies for hemodialysis vascular access dysfunction: fact or fiction! | |
CN100435755C (zh) | 药物洗脱支架 | |
CN109996569A (zh) | 用于医疗装置的药物释放涂层及其制备方法 | |
CN101513540A (zh) | 药物洗脱冠脉支架及其制备方法 | |
CN104689383A (zh) | 一种银杏内酯b在制备血管植入器械中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170215 Address after: 100006 room A305, building No. 1, East Street, Beijing, Dongcheng District, China Applicant after: Beijing Kang Rongyuan Medical Devices Co.,Ltd. Address before: 100700 Beijing, Dongcheng District shipping warehouse No. 5 Applicant before: Wang Xian |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170613 Address after: 100700 Beijing, Dongcheng District shipping warehouse No. 5 Co-patentee after: Wang Gangyin Patentee after: Wang Xian Address before: 100006 room A305, building No. 1, East Street, Beijing, Dongcheng District, China Patentee before: Beijing Kang Rongyuan Medical Devices Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180713 Address after: 100700 Department of Cardiology, Dongzhimen hospital, Beijing University of Chinese Medicine, Dongcheng District, Beijing 5 Patentee after: Wang Xian Address before: No. 5, Dongcheng District shipping bin, Beijing, Beijing Co-patentee before: Wang Gangyin Patentee before: Wang Xian |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230731 Address after: 100700 No. 5, Dongcheng District, Beijing Patentee after: DONGZHIMEN HOSPITAL OF BEIJING University OF CHINESE MEDICINE Address before: 100700 Department of Cardiology, Dongzhimen hospital, Beijing University of Chinese Medicine, Dongcheng District, Beijing 5 Patentee before: Wang Xian |